• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • DONATE
  • Pay 2023 Membership Dues
  • Join PeDRA
  • Login
MENUMENU
  • Contact Us
  • For Patients & Families
        • Patient Support
        • Patient Education
        • Community Spotlight
        • Play Eczema Counts Now!
        • Patient Advisory Committee
        • Find a Pediatric Dermatologist (from SPD)
        • Parents, advocates, and patients over the age of 18 with a direct connection or significant interest in childhood skin disease or pediatric dermatology research are encouraged to join the PeDRA network for free as Community Members.

          Apply Now!

  • Education and Events
        • Virtual Education
        • PeDRA Podcasts
        • Points of Discussion Podcast
        • Mentorship Program
        • SPD/PeDRA Journal Club
        • 2022 PeDRA Annual Conference
        • Dash for Discovery Fun Run/Walk
        • Early Investigator Support
        • Play Eczema Counts Now!
        • Events Calendar
        • Save the Date! The 2023 PeDRA Annual Conference will be held November 9-11, 2023 at the Westin Buckhead Atlanta in Atlanta, GA.

  • Research
        • Grants and Fellowships
        • Resources for Researchers
        • Survey Application
        • Study Application
        • Research Areas
        • Publications
        • Now accepting applications for the Emerging Investigator Research Grants Program and Research Fellowships Program.

  • About
        • Mission & Vision
        • Leadership & Staff
        • Annual Reports & Financials
        • News Archive
        • Our Supporters
        • Our Membership
        • Our Committees
        • Getting to Know You
        • 2022 marked PeDRA’s 10th year of pursuing the vision of changing lives and healing children with skin disease through collaboration and discovery. Visit our 10th Anniversary Page to learn more about the origin of PeDRA and the many accomplishments during the first ten years!

  • Member Login

Multicenter Retrospective Review of Beta Blocker Use in Young, Small, and Pre-term Infants for Infantile Hemangioma

October 11, 2019 By Brandon Weekes

Co-Principal Investigators:

Wendy Kim, DO – Loyola University and Beth Drolet, MD – University of Wisconsin

Overview:

This was a multicenter retrospective review. A RedCap survey was designed to capture information regarding timolol and propranolol use in premature and young infants. Investigators aimed to determine whether side effects were more likely in this population and if so, which side effects were more common. Included were infants < 8 weeks corrected gestational age who were treated for infantile hemangioma with oral propranolol 0.5 mg/kg/ day or greater, as well as infants treated with transcutaneous timolol. Excluded were infants > 8 weeks corrected gestational age treated with beta blocker for infantile hemangioma. Data collected included gestational age, birth weight, sex, age at initiation of therapy, size of infantile hemangioma, type of infantile hemangioma, indication for treatment, dosing, comorbidities, screening workup, and side effects with grading.

Status:

Complete.

Filed Under: Completed Studies

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Governance Policies
  • Financial Conflict of Interest Policy
  • Jobs at PeDRA
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Sign up to receive emails from PeDRA
Join PeDRA
Donate

Copyright © 2023 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy